71.05
-0.42 (-0.59%)
Penutupan Terdahulu | 71.47 |
Buka | 71.47 |
Jumlah Dagangan | 127,581 |
Purata Dagangan (3B) | 1,794,205 |
Modal Pasaran | 2,391,545,088 |
Harga / Pendapatan (P/E TTM) | 66.40 |
Harga / Pendapatan (P/E Ke hadapan) | 56.50 |
Harga / Jualan (P/S) | 6.81 |
Harga / Buku (P/B) | 12.63 |
Julat 52 Minggu | |
Tarikh Pendapatan | 28 Apr 2025 - 2 May 2025 |
Margin Keuntungan | 8.03% |
Margin Operasi (TTM) | 7.11% |
EPS Cair (TTM) | 1.07 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 49.80% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 70.10% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 226.72% |
Nisbah Semasa (MRQ) | 8.30 |
Aliran Tunai Operasi (OCF TTM) | 48.80 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.77 M |
Pulangan Atas Aset (ROA TTM) | 3.10% |
Pulangan Atas Ekuiti (ROE TTM) | 19.39% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Menurun | Bercampur |
Medical Devices (Global) | Menurun | Bercampur | |
Stok | TransMedics Group, Inc. | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | -1.5 |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 1.0 |
Osilator Teknikal | 4.0 |
Purata | 1.70 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 3.48% |
% Dimiliki oleh Institusi | 115.50% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 130.00 (Oppenheimer, 82.98%) | Beli |
Median | 125.00 (75.95%) | |
Rendah | 104.00 (Canaccord Genuity, 46.39%) | Beli |
Purata | 119.67 (68.44%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 96.88 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Oppenheimer | 09 May 2025 | 130.00 (82.98%) | Beli | 111.50 |
Piper Sandler | 09 May 2025 | 125.00 (75.94%) | Beli | 111.50 |
29 Apr 2025 | 105.00 (47.79%) | Beli | 92.43 | |
Canaccord Genuity | 11 Mar 2025 | 104.00 (46.39%) | Beli | 67.65 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
27 May 2025 | Pengumuman | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
20 May 2025 | Pengumuman | TransMedics to Present at Upcoming June Investor Conferences |
08 May 2025 | Pengumuman | TransMedics Reports First Quarter 2025 Financial Results |
24 Apr 2025 | Pengumuman | TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 |
02 Apr 2025 | Pengumuman | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
24 Mar 2025 | Pengumuman | SHAREHOLDER DEADLINE: TransMedics Group (TMDX) Investors Are Reminded of Deadline in Securities Action |
17 Mar 2025 | Pengumuman | ATTENTION TRANSMEDICS GROUP (TMDX) SHAREHOLDERS: Securities Fraud Lawsuit Filed Against TransMedics Group (TMDX) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |